Hypofractionated proton beam therapy for centrally located lung cancer.
Centrally located lung cancer
lung cancer
proton beam therapy
radiotherapy
stereotactic body radiation therapy
Journal
Journal of medical imaging and radiation oncology
ISSN: 1754-9485
Titre abrégé: J Med Imaging Radiat Oncol
Pays: Australia
ID NLM: 101469340
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
received:
31
01
2019
accepted:
19
04
2019
pubmed:
31
5
2019
medline:
8
2
2020
entrez:
31
5
2019
Statut:
ppublish
Résumé
To clarify the efficacy and safety of hypofractionated proton beam therapy (PBT) for centrally located lung cancer. We retrospectively reviewed 39 patients who received hypofractionated [≧3 Gy (relative biological effectiveness: RBE)/fraction] PBT for centrally located cT1-2N0M0 (8th edition) lung cancer between 1999 and 2015. A tumour within 2 cm of the proximal bronchial tree was defined as a centrally located tumour. Twenty-four patients (62%) were treated with 80 Gy (RBE) in 20 fractions (112 Gy Hypofractionated PBT may be a very safe and effective treatment option for centrally located early lung cancer.
Identifiants
pubmed: 31145553
doi: 10.1111/1754-9485.12901
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
552-556Subventions
Organisme : Ministry of Health and Welfare
Informations de copyright
© 2019 The Royal Australian and New Zealand College of Radiologists.